Initial Results from National Oncologic PET Registry (NOPR) have been published recently in the Journal of Clinical Oncology. The results provide impressive evidence for the substantial impact of PET imaging across all cancers.
This issue we are discussing several important topics in molecular imaging and medicine. One addresses the need for developing tools not only to monitor therapeutic responses, but also to stratify patients into the treatments that are most likely to result in significant responses. This concept can be applied not only to oncology, but also is highly relevant in patients with neurologic and cardiac diseases.
This issue provides discussions about potential risks associated with diagnostic tests in pediatric patients, PET probes for imaging neuroinflammation and neurodegenerative diseases, as well as emerging hybrid imaging technologies such as PET/MRI.
This issue highlights the emergence of PET/MR, which follows the introduction of SPECT/CT and PET/CT that have convincingly shown that multimodality imaging can result in significantly improved disease characterization.
The cover story in this issue discusses the role of PET imaging for assessing therapeutic responses in cancer. Over the past 15 years, a large body of evidence has demonstrated that FDG-PET imaging is uniquely useful to assess treatment responses in cancer patients.
This issue provides updates on several important applications of molecular imaging. The cover story presents novel ideas to better identify patients who are at risk for or have coronary artery disease.